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Abstract 
Background: Stroke immediately sets into motion sustained excitotoxicity and calcium dysregulation, causing 
aberrant activity in neuronal nitric oxide synthase (nNOS) and an imbalance in the levels of nitric oxide (NO). Drugs 
targeting nNOS-originated toxicity may therefore reduce stroke-induced damage. Recently, we observed that a redox-
modulating agent of the NO metabolome, S-nitrosoglutathione (GSNO), confers neurovascular protection by reduc-
ing the levels of peroxynitrite, a product of aberrant NOS activity. We therefore investigated whether GSNO-mediated 
neuroprotection and improved neurological functions depend on blocking nNOS/peroxynitrite-associated injurious 
mechanisms using a rat model of cerebral ischemia reperfusion (IR).
Results: IR increased the activity of nNOS, the levels of neuronal peroxynitrite and phosphorylation at Ser1412 of 
nNOS. GSNO treatment of IR animals decreased IR-activated nNOS activity and neuronal peroxynitrite levels by reduc-
ing nNOS phosphorylation at Ser1412. The Ser1412 phosphorylation is associated with increased nNOS activity. Sup-
porting the notion that nNOS activity and peroxynitrite are deleterious following IR, inhibition of nNOS by its inhibitor 
7-nitroindazole or reducing peroxynitrite by its scavenger FeTPPS decreased IR injury. GSNO also decreased the activa-
tion of AMP Kinase (AMPK) and its upstream kinase LKB1, both of which were activated in IR brain. AMPK has been 
implicated in nNOS activation via Ser1412 phosphorylation. To determine whether AMPK activation is deleterious in the 
acute phase of IR, we treated animals after IR with AICAR (an AMPK activator) and compound c (an AMPK inhibitor). 
While AICAR potentiated, compound c reduced the IR injury.
Conclusions: Taken together, these results indicate an injurious nNOS/peroxynitrite/AMPK cycle following stroke, 
and GSNO treatment of IR inhibits this vicious cycle, resulting in neuroprotection and improved neurological function. 
GSNO is a natural component of the human body, and its exogenous administration to humans is not associated with 
any known side effects. Currently, the FDA-approved thrombolytic therapy suffers from a lack of neuronal protective 
activity. Because GSNO provides neuroprotection by ameliorating stroke’s initial and causative injuries, it is a candidate 
of translational value for stroke therapy.
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Background
Ischemic stroke (almost 87% of all strokes) and transient 
ischemic attack (TIA) obstruct oxygen and nutrient sup-
ply to the brain. Instantaneously, the obstruction of blood 
supply causes necrotic neuronal death in the injury core; 
however, even greater apoptotic neuronal damage is 
caused by nitroxidative stress and neuroinflammation in 
the cortical penumbra and hippocampal areas [1]. Neu-
ronal nitric oxide synthase (nNOS)-derived nitroxidative 
stress occurs due to calcium homeostasis derailment, 
excitotoxicity, and an imbalance in the nitric oxide (NO) 
metabolome. These redox-based injuries later hamper 
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functional recovery [2, 3]. Other than thrombolysis by 
tissue plasminogen activator, which offers only a short 
window of treatment (~3–4  h) beyond which severe 
damage results, an effective neuroprotective stroke ther-
apy is not available mainly due to limited understanding 
of the initial nitroxidative signaling mechanisms of the 
disease [1].
nNOS contributes approximately 90% to NOS activity 
in normal rodents [4]. Of the three known nitric oxide 
synthases, nNOS activity plays a critical role in neu-
ronal cell death during the acute ischemia reperfusion 
(IR) phase [5]. Inhibition of nNOS activity following IR 
[5, 6] has been shown to be neuroprotective and nNOS 
KO mice show reduced infarct volume [4, 7–10], indicat-
ing that nNOS plays a significant role in IR injury. Like 
nNOS, endothelial nitric oxide synthase is also aberrantly 
activated early after stroke. However, endothelial nitric 
oxide synthase is localized primarily in endothelium and 
endothelial nitric oxide synthase -derived NO, via per-
oxynitrite, has been associated with blood–brain bar-
rier leakage, cerebral hemorrhage and edema [11–13]. In 
rodent, inducible nitric oxide synthase is expressed from 
~12  h to several days after IR and its immunoreactivity 
is present mainly in inflammatory cells and endothe-
lium [14–16]. Therefore, the focus of this acute IR study 
is to investigate the mechanisms of nNOS regulation for 
developing stroke therapy.
Recent reports document that S-nitrosylation of nNOS 
regulates its activity [11, 17], in addition to phosphoryla-
tion/dephosphorylation [18]. In resting neurons, nNOS 
is inhibited mainly by S-nitrosylation of Cys331; how-
ever, immediately following stroke injury, nNOS is acti-
vated by NMDA receptor-mediated excitotoxicity and a 
sustained calcium influx through site-specific phospho-
rylation (Ser1412) and denitrosylation (Cys331). In such an 
environment, nNOS-derived NO is converted to perox-
ynitrite by an instantaneous diffusion-limited reaction 
with superoxide [19]. Peroxynitrite can activate AMPK 
via the activation of upstream AMPK kinase LKB1, thus 
maintaining a vicious cycle of its own production [20].
The interplay between nNOS and neuronal AMPK dur-
ing the acute phase of stroke is now recognized to con-
tribute to neuronal loss [21]. AMPK is a cellular energy 
sensor and an important potential target for stroke treat-
ment. However, the timing, duration and degree of its 
activation are critical for the outcome of stroke injury 
[21, 22]. AMPK is activated during decreased cellular 
energy supply (AMP vs. ATP ratio). It is highly expressed 
in neurons (AMPKα2) and is rapidly activated in an 
energy-deprived status such as that which follows stroke 
[23]. Its activation during the acute phase of IR is delete-
rious; indeed, both pharmacological inhibition and gene 
deletion of AMPK were found to be neuroprotective [23]. 
AMPK has been reported to phosphorylate nNOS [24, 
25]. During acute IR disease with dysregulated calcium 
flux, AMPK activation possibly keeps nNOS hyperacti-
vated via sustained phosphorylation of Ser1412 of nNOS. 
This phenomenon results in Cys331 denitrosylation, 
leading to sustained peroxynitrite formation and thus 
peroxynitrite-mediated neuronal loss. In contrast to per-
oxynitrite, an endogenous signaling molecule of the NO 
metabolome, S-nitrosoglutathione (GSNO), has been 
documented to reduce the levels of peroxynitrite as well 
as neuronal cell death in a number of neurodegenerative 
diseases, including stroke [11, 26, 27], traumatic brain 
injury [28, 29] and vascular dementia [30]. It can inhibit 
the activity of nNOS under excitotoxic conditions via 
the S-nitrosylation of Cys331 of nNOS [17, 18], leading to 
reduced formation of peroxynitrite.
GSNO executes its action mainly via S-nitrosylation 
of target proteins [31]. In stroke pathology, the levels 
of GSNO and the consequent S-nitrosylated proteins 
are believed to decrease due to four major reasons: (a) 
decreased oxygen supply under ischemic/hypoxic condi-
tion reduces GSNO biosynthesis; (b) excessive superoxide 
formed during reperfusion instantaneously reacts with 
nitric oxide synthase (NOS)-derived NO, forming perox-
ynitrite and thus reducing NO bioavailability for GSNO 
biosynthesis; (c) biosynthesis of GSNO is decreased as 
a result of reduced levels of glutathione (redox imbal-
ance) and NO (due to its reaction with superoxide) under 
IR conditions. Furthermore, NO reacts slowly with glu-
tathione as compared with superoxide [32]; and (d) in the 
inflammatory environment, the expression of the GSNO-
degrading enzyme GSNO reductase is increased [33], 
leading to reduced levels of GSNO. Therefore, the subject 
of investigation for this study was the exogenous supple-
mentation of GSNO to down regulate the aberrant activ-
ity of nNOS and AMPK, leading to neuroprotection and 
functional recovery.
The overall goal of the present study is to investigate 
whether GSNO provides neuroprotection by reducing 
the levels of peroxynitrite via the inhibition of nNOS 
activity. Our initial studies show that treatment of IR 
animals with GSNO reduced phosphorylation at Ser1412, 
possibly via the inhibition of LKB1 and AMPK activi-
ties, and thus attenuated nNOS activity and peroxyni-




GSNO was purchased from World Precision Instru-
ments (Sarasota, FL) and dorsomorphin dihydrochlo-
ride (Compound c) from Tocris Bioscience (Bristol, UK). 
5-Amino-1-[(2R,3S,4R,5R)-tetrahydro-3,4-dihydroxy-
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5-(hydroxymethyl)furan-2-yl]-1H-imidazole-4-carboxa-
mide (AICAR) and 5,10,15,20-tetrakis(4-sulfonatophenyl) 
porphyrinato iron (III) (FeTPPS) were obtained from 
Abcam (Cambridge, UK) and Calbiochem, (La Jolla, CA, 
USA), respectively. All other chemicals and reagents used 
were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), unless stated otherwise.
Animals
Animals were male Sprague–Dawley rats weighing 
between 250 and 290 g at the time of surgery. Number of 
animals used in this study is described in figure legends. 
All animals received humane care in compliance with the 
Medical University of South Carolina’s (MUSC) guidance 
and the National Research Council’s criteria for humane 
care. Animal procedures were approved by the institu-
tional animal care and use committee of MUSC.
Experimental groups, drugs and dose
The animals were randomly divided into  eight groups: 
(1) ischemia reperfusion treated with vehicle (IR), (2) 
IR  +  GSNO treatment (GSNO), (3) IR  +  compound c 
treatment (Comp c), (4) IR + AICAR treatment (AICAR), 
(5) IR + FeTPPS treatment (FeTPPS), (6) IR + 7-nitroin-
dazole (7-NI) treatment, (7) IR + AICAR + GSNO, and 
(8) sham-operated treated with vehicle (Sham). The num-
ber of animals used in each experiment is indicated in fig-
ure legends. In the GSNO treatment group, the rats were 
administered freshly prepared GSNO (0.25  mg/kg body 
weight), which was dissolved in sterile saline (~250  μl) 
and administered intravenously slowly at reperfusion or 
as stated. While 7-NI (50 mg/kg ip) was administered at 
the reperfusion, AICAR (500 mg/kg, ip), Comp c (20 mg/
kg, ip) and FeTPPS (3 mg/kg, iv) were administered 1 h 
after reperfusion. The dosage of treatment was based 
on our previously reported dose response curve study 
in a rat model of IR or effective dose reported in stroke 
IR models [11, 23, 34]. Physiological parameters did not 
alter after the treatments. Details of the study on physi-
ologic parameters in IR rats have been reported earlier 
[26].
Middle cerebral artery occlusion rat model
Rats were anesthetized by ketamine hydrochloride 
(90  mg/kg body weight) and xylazine (10  mg/kg body 
weight) administered ip. Stroke was induced for 60 min 
by left middle cerebral artery occlusion using an intralu-
minal filament as previously described [26, 35]. To ensure 
the obstruction, regional cerebral blood flow was moni-
tored during the occlusion and early reperfusion [26]. 
Reperfusion was established by withdrawal of the fila-
ment. After specified time points, animals were sacrificed 
with an overdose of ketamine hydrochloride.
Evaluation of ischemic infarct
Coronal sections  (2  mm) were immersed in 1% solu-
tion of TTC in phosphate-buffered saline (PBS, pH 7.4) 
at 37°C for 15  min, as described previously [36]. After 
staining, infarctions were measured using Scion Image 
software (Scion Corp., Frederick, MD, USA). Total 
infarct area was multiplied by the thickness of the brain 
sections to obtain infarct volume, as described previ-
ously [27]. In order to minimize the error introduced 
by edema and liquefaction after infarction, an indirect 
method for calculating infarct volume was used [35, 37]. 
The non-infarcted area in the ipsilateral hemisphere was 
subtracted from that in the contralateral hemisphere, 
and infarct volume was calculated using the following 
formula: corrected percentage of infarct volume = (con-
tralateral hemispheric volume − ipsilateral non-infarcted 
volume)/contralateral hemispheric volume.
Evaluation of neurological score
Neurological deficits were evaluated by an observer 
blinded to the identity of the groups. A neurological 
grading system with a 4-point scale (0–3), as described 
previously [27], was used: 0, no observable neurological 
deficit (normal); 1, failure to extend right forepaw on lift-
ing the whole body by tail (mild); 2, circling to the con-
tralateral side (moderate); 3, leaning to the contralateral 
side at rest or no spontaneous motor activity (severe). 
The animals not showing paralysis at 1  h after middle 
cerebral artery occlusion were excluded from the study 
because the reduction of blood flow may not have pro-
duced an infarction of adequate size to cause quantifiable 
neurological deficits in those animals.
Histological evaluation
At hour 4 post-IR, the animals were sacrificed and per-
fused before the brain was fixed in 10% formalin. The 
tissue was processed for histology and immunohisto-
chemistry (IHC) as previously described [36]. The brain 
sections (8 µM thick) were stained as described [36] with 
Nissl, Bielschowsky’s silver, H&E. The histological analy-
sis was performed in the penumbra area by an investiga-
tor who was blinded to the experimental group. While 
Nissl staining determines neuronal cell damage, H&E 
indicates overall tissue damage. Bielschowsky’s silver 
staining provides indication of the loss of axonal integrity.
Immunohistochemistry (IHC) analysis
Paraffin-embedded sections from the formalin-fixed 
brain tissues were stained for 3-NT (Abcam Cat# ab7048, 
RRID:AB_305725) and NeuN (Merck Cat# MAB377, 
RRID:AB_11210778), as described previously [29]. In brief, 
the brain tissue sections were deparaffinized, sequentially 
rehydrated in graded alcohol, and then immersed in PBS 
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(pH 7.4). Slides were then microwaved in antigen unmask-
ing solution (Vector Labs), cooled and washed 3 times 
for 2 min in PBS. Slides were then blocked by 5% non-fat 
dry milk in PBS for 20 min at room temperature. Sections 
were incubated overnight with antibodies of 3-NT and 
NSE. They were then rinsed 3 times for 5 min in PBS con-
taining 0.1% Tween-20. Secondary anti-mouse IgG, conju-
gated with Texas red (Vector Laboratories Cat# TI-2000, 
RRID:AB_2336178) for 3-NT and secondary anti-rabbit 
IgG, conjugated with FITC (Vector Laboratories Cat# 
FI-1000, RRID:AB_2336197) for NSE were incubated on 
slides for 60 min. All sections were examined for immunore-
activity in the penumbra area using an Olympus microscope 
equipped for epifluorescence and DP Controller software. 
Figures were compiled in Adobe Photoshop software.
For double labeling, sections were incubated first with 
an antibody of 3-NT followed by NSE. For immunofluo-
rescent double-labeling, immune complexes were visu-
alized with anti-mouse IgG (Vector Laboratories Cat# 
TI-2000, RRID:AB_2336178) and anti-rabbit IgG (Vec-
tor Laboratories Cat# FI-1000, RRID:AB_2336197). In 
another set of experiments, sections were also incubated 
with FITC or Texas Red conjugated IgG without the pri-
mary antibody as a negative control to confirm the speci-
ficity of the primary antibody. Slides were examined for 
immunofluorescence using an Olympus microscope 
equipped with an epifluorescence filter and Adobe Pho-
toshop software [29].
Western blot analysis
Western blot was performed using fresh or frozen tis-
sue, as previously described [11]. The following antibod-
ies were used; phospho-Thr172-AMPKα (Cell Signaling 
Technology Cat# 2535S RRID:AB_331250), AMPKα (Cell 
Signaling Technology Cat# 2532S RRID:AB_10694064), 
phospho-Ser79-ACC Cell Signaling Technology Cat# 
3661S RRID:AB_330337) and phospho-Ser428-LKB1 (Cell 
Signaling Technology Cat# 3482S RRID:AB_2198321), 
nNOS (Abcam Cat# ab1376 RRID:AB_300614), phospho 
nNOS Ser1417, equivalent to human Ser1412 (Abcam Cat# 
ab90443 RRID:AB_2049208) and β-actin (Sigma-Aldrich 
Cat# A3853 RRID:AB_262137), followed by horserad-
ish peroxidase-conjugated, goat anti-rabbit secondary 
antibody (Jackson ImmunoResearch Cat# 111-035-045 
RRID:AB_2337938). Protein concentrations were deter-
mined using protein assay dye from Bio-Rad Laboratories 
(Hercules, CA). Densitometry of protein expression was 
performed using a GS800 calibrated densitometer from 
Bio-Rad laboratories (Hercules, CA).
NOS activity assay
NOS activity in the penumbra brain area was determined 
by the conversion of L-[4,5-3H] arginine (American 
Radiolabeled, Inc., St. Louis, MO, USA) to L-[4,5-3H] 
citrulline in the presence or absence of the competitive 
NOS inhibitor L-NAME using an NOS assay kit from 
Cayman Chemicals (Ann Arbor, MI) and following the 
instructions described therein. Total cNOS activity was 
determined by subtracting calcium independent NOS 
activity. The nNOS inhibitor, 7-NI (50  mg/kg), and the 
NOS inhibitor, L-NAME (30  mg/kg), were used to dif-
ferentiate between endothelial nitric oxide synthase and 
nNOS activity [38]. The activity was expressed as pmol/
mg protein/min.
NO assay
The levels of NO (as nitrite) in the penumbral brain 
area were determined using a Roche’s test “Nitric oxide 
colorimetric assay” kit. The estimation was based on 
the following reaction: nitrites  +  sulfanilamide  + 
N-(1-naphthyl)-ethylene-diamine dihydrochloride and 
yields a reddish-violet diazo dye whose absorbance was 
measured in the visible range at 540 nm. The assay was 
performed as described by the manufacturer.
Statistical evaluation
Statistical analysis was performed using Graph pad prism 
5.01 software [39]. Statistical significance was determined 
using paired or unpaired students’ t test as appropriate or 
one-way ANOVA with Tukey post hoc for three or more 
groups. Values were expressed as mean ± standard devi-
ation (SD). A p value less than 0.05 was considered statis-
tically significant.
Results
GSNO inhibits nNOS activity and decreases the levels 
of neuronal peroxynitrite (3‑nitrotyrosine; 3‑NT) 
following IR
Increased nNOS activity and the participation of nNOS-
derived peroxynitrite in stroke injury have been reported 
[7]. However, the timing and the relationship of perox-
ynitrite formation with neuronal degeneration are less 
understood. Furthermore, the mechanisms of nNOS 
regulation by products of the NO metabolome, including 
GSNO, are not clear. We observed an increased degree 
of nNOS activity (p < 0.001) as early as 1 h after reper-
fusion, and the treatment with GSNO at 0  h after rep-
erfusion significantly decreased (p  <  0.001) the nNOS 
activity (Figure  1a). The increased nNOS activity corre-
lated with the decreased levels (p < 0.001) of NO in the 
IR brain (Figure  1b), indicating that NO is being con-
sumed by superoxide to make peroxynitrite. Accord-
ingly, enhanced expression of 3-NT (Figure  1c, as a 
marker of peroxynitrite) was observed in neurons from 
IR brain (Figure  1d, colocalization of 3-NT with neu-
ronal marker NeuN). GSNO treatment of IR not only 
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increased NO bioavailability (p < 0.05 vs. IR, Figure 1b) 
but also reduced the expression of 3-NT, thus suggesting 
that GSNO inhibited nNOS activity. Previously, we have 
also reported increased levels of 3-NT at 4 h [11] as well 
as 24  h [26] following IR. These results indicate that IR 
brain accumulates and maintains sustained levels of per-
oxynitrite in the acute phase of IR.
GSNO reduces neuronal degeneration and protects axon/
tissue integrity following IR
To examine whether GSNO-mediated decreased levels 
of peroxynitrite in IR brain correlate with neuroprotec-
tion, we evaluated neuronal degeneration using Nissl 
(Figure  2a), axonal integrity using Bielschowsky silver 
(Figure  2b), and tissue structure using H&E (Figure  2c) 
in the fixed brain sections at 4 h after IR. Nissl staining 
showed a remarkable number of degenerating neurons in 
IR (indicated by black arrow); these levels were reduced 
in the GSNO group (blue arrow showing intact neu-
rons). Bielschowsky silver staining is a marker of axonal 
integrity. It was also reduced in IR (Figure 2b). The treat-
ment with GSNO protected axonal integrity, as indicated 
by the enhanced staining of Bielschowsky silver in the 
GSNO brain. H&E staining showed that IR-mediated 
tissue deformation (red arrow) and pyknosis of neurons 
(black arrow) were blocked by GSNO treatment. These 
data indicate that GSNO provides neuroprotection.
GSNO inhibits nNOS activity by decreasing 
phosphorylation at Ser1412 of nNOS following IR
Immediately after stroke injury, nNOS is activated by 
NMDA receptor-mediated excitotoxicity and calcium 
Figure 1 Effect of GSNO on the activity of nNOS and the levels of NO and peroxynitrite (3-NT) in ipsilateral (penumbra) area of the IR brain. nNOS 
activity at 1 h (a), NO levels at 1 h (b) and peroxynitrite levels (3-NT, IHC [c] and IHC colocalization of 3-NT and neuronal marker NeuN [d]) at 1 h after 
reperfusion were determined. GSNO were administered 0 h after reperfusion began. NO levels in Sham animals were 39.8 ± 4.2 nmol/mg protein. 
Data are presented as mean ± SD (n = 5). ***p < 0.001 vs. Sham, ###p < 0.001, #p < 0.05 vs. IR, $$p < 0.01, $p < 0.05 vs. Sham.
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influx through site specific phosphorylation (Ser1412) 
[18]. In such an environment, nNOS-derived NO is con-
verted to peroxynitrite by an instantaneous diffusion 
limited reaction with superoxide [19]. Peroxynitrite, in 
turn, maintains aberrant activity of nNOS via oxidative 
mechanisms. We investigated whether GSNO inhib-
its nNOS activity as shown in Figure 1a via the reversal 
of phosphorylation (Ser1412). We observed IR-induced 
increased levels (p < 0.001) of phosphorylated Ser1412 at 
1  h of reperfusion (Figure  3a, b), resulting in increased 
nNOS activity as shown in Figure  1a, thus render-
ing nNOS “aberrant” and causing sustained accumula-
tion of peroxynitrite (Figure 1c). GSNO treatment of IR 
decreased the levels the IR-induced phosphorylation 
of Ser1412 (p  <  0.001, Figure  3a, b), resulting in reduced 
nNOS activity (Figure  1a) as well as decreased levels of 
neuronal peroxynitrite (Figure 1c, d).
nNOS inhibitor 7‑NI treatment of IR provides limited 
protection compared with GSNO following IR
7-NI, a selective nNOS inhibitor, is reported to reduce 
infarct volume in IR models [6, 40]. However, its efficacy 
is limited due to irreversible nNOS inhibition and a nar-
row therapeutic window of treatment [40]. We compared 
the efficacy of 7-NI with GSNO after administering both 
Figure 2 Effect of GSNO on neuronal degeneration and axonal loss in ipsilateral (penumbra) area of IR brain at 4 h after reperfusion. Nissl staining 
a shows significant number of degenerating neurons (black arrow) in IR compared with GSNO and sham groups (intact neurons are shown by blue 
arrows). Bielshowsky silver and b H&E stainings c show loss of axonal and tissue integrity (red arrow), respectively, in IR compared with GSNO and 
sham. IR also shows pyknosis of neurons (black arrow). Photomicrographs are representative of n = 3 in each group.
Figure 3 Effect of GSNO on nNOS phosphorylation status in ipsilat-
eral (penumbra) area of IR brain. Phosphorylation at Ser1417 [equivalent 
to1412 in human] of nNOS and its expression (a) and their densitometry 
(b) were evaluated at 1 h of reperfusion. Data are presented as 
mean ± SD (n = 5). ***p < 0.001 vs. Sham and GSNO.
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drugs at 1  h of reperfusion. Treatment with both drugs 
significantly reduced brain infarctions (p  <  0.001, Fig-
ure 4a–c) compared with IR, determined at 24 h after IR. 
However, the efficacy of GSNO was greater than 7-NI 
in terms of reduction of infarct volume (p  <  0.001, Fig-
ure  4c). Furthermore, GSNO and not 7-NI significantly 
improved neurological score (p < 0.01, Figure 4d).
IR‑induced AMPK activation is reversed by GSNO treatment 
following IR
nNOS activation occurs via phosphorylation of Ser1412 
and thus its increased activity is regulated by several 
kinases, including Akt and AMPK. While Akt is inhibited 
[20], AMPK is activated following IR [23]. Peroxynitrite is 
known to activate AMPK via its upstream kinase LKB1, 
thus increasing nNOS activity. Consistent with previous 
reports, we observed IR-induced activation of AMPK 
(pAMPK), which was blunted by GSNO treatment of IR 
as shown by western analysis (p < 0.001, Figure 5b, b′) at 
1 h after reperfusion. GSNO also inhibited (p < 0.001) IR-
induced activation of LKB1, (Figure  5a, a′) and ACC, a 
substrate of AMPK (Figure 5b, b′).
AMPK inhibitor Comp c and peroxynitrite scavenger 
FeTPPS decrease whereas AMPK activator AICAR increases 
the injury following IR
AMPK activation in the acute phase of IR is deleterious, 
and these injurious effects are linked with increased per-
oxynitrite levels [23, 41]. Peroxynitrite activates AMPK 
through LKB1activity which, in turn, may phosphoryl-
ate nNOS(Ser1412), leading to peroxynitrite formation. 
We observed that the AMPK inhibitor Comp c as well 
as the peroxynitrite scavenger FeTPPS-treated animals 
(at 1  h after IR) had significantly reduced (p  <  0.001) 
infarct volume (Figure 6a) and improved (p < 0.001) neu-
rological score (Figure 6b). In contrast, the AMPK acti-
vator AICAR treated animals at 1  h after reperfusion 
had increased (p < 0.001) levels of infarct volume and a 
higher (p  <  0.001) degree of neurological deficits (Fig-
ure  6a, b). However, AICAR animals prior-treated with 
GSNO (at 0 h of reperfusion) had less (p < 0.001) injury 
and reduced (p  <  0.001) neurological deficits compared 
with AICAR-alone animals. However, AICAR +  GSNO 
group had significantly more (p < 0.001) infarct volume 
and neurological deficits. As previously reported [26], 
GSNO treatment of IR showed remarkable (p < 0.001 vs. 
IR) neuroprotection and functional recovery (p  <  0.001 
vs. IR) when administered at reperfusion (Figure 6a, b).
Discussion
Stroke is one of the most disabling conditions in the 
United States. The most severe injury after ischemia or 
reperfusion happens within a couple of hours of initial 
stroke, leading to the wisdom in stroke care that “time 
is brain” [42]. This concept demands focus on the initial 
critical events and their injury mechanisms for develop-
ing an effective therapy using clinically relevant animal 
models.
Figure 4 Effect of nNOS inhibitor 7-NI and GSNO on brain infarctions and neurological score. Representative TTC stained sections (#3 and 4 out 
of six consecutive sections from cranial to caudate region) (a), infarct area (b), infarct volume (c) and neurological score (d) at 24 h of the reperfu-
sion after 60 min middle cerebral artery occlusion. Both 7-NI and GSNO were administered 1 h after reperfusion began. Data are presented as 
mean ± SD (n = 5). ***p < 0.001, **p < 0.01 vs. IR, +++p < 0.001 vs. 7-NI.
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Neuroimaging data in patients who have stroke or tran-
sient ischemic attack show that the territory of the mid-
dle cerebral artery branches suffers from multiple infarcts 
more frequently than other areas [43]. Inflammation and 
secondary brain damage also occur in similar areas after 
inappropriate thrombolytic therapy [44]. Therefore, we 
used a rat model of middle cerebral artery occlusion fol-
lowed by reperfusion. Animal models of focal cerebral 
ischemia using the middle cerebral artery occlusion tech-
nique are recognized as physiologically relevant to stroke 
in humans [45, 46]. After stroke, the core injury site dies; 
however, the area surrounding the core (penumbra) 
survives if treated and perfused properly. Therefore, we 
selected salvageable penumbra tissue for this study. Our 
previous studies have shown that the GSNO-mediated 
mechanisms reduced peroxynitrite levels and inflamma-
tion, protected against blood–brain barrier leakage, and 
improved neurobehavioral function; however, the mech-
anisms of GSNO-mediated down regulation of peroxyni-
trite-induced injury in IR are not well understood. nNOS 
activation due to calcium dysregulation and excitotox-
icity has been documented among the causative factors 
in stroke [18], and the mechanism of S-nitrosylation has 
Figure 5 Effect of GSNO on LKB1, ACC and AMPK phosphorylation status in ipsilateral (penumbra) area of IR brain. Western blot at 1 h of reperfu-
sion showing phosphorylation of pLKB1 (a, a′), pACC and pAMPK/pACC (b, b′). GSNO was administered at 0 h after reperfusion began. Data are 
presented as mean ± SD (n = 5). ***p < 0.001, **p < 0.01 vs. Sham and GSNO.
Figure 6 Effect of AMPK inhibitor Comp c, peroxynitrite scavenger 
FeTPPS and AMPK activator AICAR on infarct volume and neurologi-
cal score. Infarct volume (a calculated from TTC stained sections) and 
neurological score (b) at 24 h of IR. While Comp c, FeTPPS and AICAR 
were administered 1 h, GSNO was administered 0 h after reperfusion 
began. Data are presented as mean ± SD (n = 5). ***p < 0.001 vs. IR, 
$$$p < 0.001 vs. AICAR, +++p < 0.001 vs. GSNO.
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been shown to inhibit nNOS activity [17]. Therefore, we 
hypothesized that GSNO treatment of IR reduces nNOS 
activity and peroxynitrite levels, leading to neuroprotec-
tion and functional recovery as depicted in Figure 7.
Early neuronal cell death in IR is caused by nNOS acti-
vation and peroxynitrite formation [7]. Peroxynitrite 
(3-NT)-positive neurons are more susceptible to cell 
death [47], indicating that reducing neuronal peroxyni-
trite may translate into reduced neuronal cell death, lead-
ing to tissue protection and functional improvements. 
In neurons, peroxynitrite originates from excitotoxic-
ity-induced aberrant nNOS activity [7]. nNOS activ-
ity is dynamically regulated by NO metabolome, which 
includes GSNO. NO from nNOS forms GSNO, if super-
oxide levels are low; however, peroxynitrite is formed 
when superoxide levels significantly exceed NO levels 
[48, 49]. Peroxynitrite can keep nNOS under sustained 
aberrant activation status via the up regulation of phos-
phorylation of Ser1412, thus maintaining its own forma-
tion and causing sustained neuronal cell death. In this 
study, we tested whether GSNO down regulates aber-
rant nNOS activity by reducing the levels of peroxynitrite 
through reversing peroxynitrite-induced phosphoryla-
tion/dephosphoryaltion mechanisms as elucidated in 
Figure 7.
nNOS activation requires NMDA-receptor-mediated 
Ca2+ influx, leading to secondary modification of nNOS, 
such as denitrosylation of Cys331, and phosphorylation of 
Ser1412 [50]. Several kinases, including CaMKIIα, PKA, 
Akt (PKB), and AMPK, and phosphatases, including PP1, 
PP2A, and PP2B, have been reported to be involved in 
phosphorylation and dephosphorylation of Ser1412 [24, 
47, 50–54], but their regulation by peroxynitrite and 
GSNO is not understood. We observed that IR induced 
increased levels of phosphorylated Ser1412 as early as 1 h 
following IR (Figure 3). IR also increased nNOS activity 
(Figure 1a) and neuronal peroxynitrite levels (Figure 1c, 
d). These IR-induced effects were blunted by GSNO 
treatment of IR as shown by reduced levels of perox-
ynitrite (measured as 3-NT expression) (Figure  1c, d) 
and reduced levels of phosphorylated Ser1412 (Figure  3). 
GSNO also reduces neuronal loss and maintains axonal 
integrity (Figure 2). Inhibition of nNOS by 7-NI, a selec-
tive nNOS inhibitor, has previously been shown to pro-
vide neuroprotection as it reduces infarct volume in IR 
models [40]. However, the efficacy of 7-NI is limited due 
to irreversible nNOS inhibition and narrow therapeu-
tic window of treatment [6, 40]. We observed reduced 
infarct volume in 7-NI animals compared with IR; how-
ever, GSNO-treated animals had a significantly greater 
decrease in the infract volume (Figure 4) compared with 
the 7-NI. GSNO, but not 7-NI, also improved neurologi-
cal score (Figure  4). Furthermore, 7-NI treatment of IR 
has been shown to significantly reduce cerebral blood 
flow [55], indicating that sustained and suicidal inhibi-
tion of nNOS may have drastically reduced the NO levels 
required for blood flow as well as for other NO-depend-
ent physiological function. Contrary to 7-NI, GSNO 
increases NO bioavailability (Figure  1b), enhances the 
blood flow and mimics several beneficial functions of 
NOS-derived NO [26]. Moreover, GSNO maintains the 
homeostasis of the NO metabolome by regulating nNOS 
activity in a reversible (feedback) manner via S-nitrosyla-
tion and signaling mechanisms through the regulation of 
its kinases.
Decreased activation of AMPK and reduced IR injury 
in nNOS KO mice indicate that AMPK activation is 
dependent on nNOS activity [23]. AMPK activity has 
been reported to phosphorylate Ser1412 of nNOS, thus 
increasing nNOS activity. Unlike AMPK, Akt is inhibited 
Figure 7 Schematic showing hypothesized nNOS/peroxynitrite-
mediated deleterious events and GSNO-mediated targets. IR-induced 
excitotoxicity and calcium dysregulation cause aberrant nNOS activa-
tion, peroxynitrite formation and LKB1/AMPK activation. GSNO treat-
ment of IR blocks the vicious cycle by inhibiting the aberrant activity 
of nNOS and LKB1/AMPK, leading to neuroprotection and improved 
neurobehavioral function.
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following IR in a time dependent manner, likely by per-
oxynitrite [20]. Our data showing decreased activity of 
LKB1, AMPK and ACC by GSNO indicate that GSNO 
can reduce nNOS activity through the reversal of AMPK 
activation (Figure  5). These observations indicate that 
peroxynitrite, nNOS and AMPK activities participate in 
a vicious cycle leading to neuronal loss and functional 
deficits. Multiple lines of evidence indicate that activa-
tion of AMPK could result in detrimental outcomes and 
that restraining AMPK activity confers neuroprotective 
effects in certain types of brain injury, such as stroke 
and Alzheimer’s disease [41, 56]. On the one hand, acti-
vation of AMPK in response to cellular stress is consid-
ered protective and has been established as important in 
enhancing the lifespan based on studies primarily from 
non-mammalian systems [57, 58]; additionally, the anti-
aging effects of AMPK activation have been proposed 
to protect against neurodegenerative diseases [59]. It is 
hypothesized that the metabolic consequences of sus-
tained and aberrant activation of AMPK in the absence 
of energy deficiency is distinct from those during stress 
(ATP depletion) conditions. Moreover, the outcome of 
AMPK activation is dependent on its substrate and the 
micro environment. Hypoxia/ischemia increases AMPK 
phosphorylation and the activity which is likely inde-
pendent of cytosolic AMP levels [23, 41]. IR-mediated 
deleterious activity of AMPK may result from direct 
phosphorylation of Thr172 by its upstream kinase LKB1. 
Peroxynitrite has been reported to be potent activator of 
LKB1/AMPK [60]. In such a case, the ability of AMPK 
to maintain energy homeostasis would be overwhelmed, 
and its detrimental effects would in turn be amplified. On 
the other hand, activation of AMPK in response to thera-
peutic activation or modest and transient stress, includ-
ing therapeutic exercises, would likely be protective in 
restoring the homeostasis of energy metabolism.
Our data on nNOS and AMPK are consistent with the 
notion that sustained activation of AMPK results in det-
rimental effects in stroke [23, 41]. AMPK activation leads 
to the aberrant activation of nNOS, which in turn pro-
duces peroxynitrite, the strongest oxidizing agent, caus-
ing neuronal cell death. AMPK inhibition, resulting in 
neuroprotection and reduced levels of peroxynitrite, sup-
ports the hypothesis that AMPK activation in the acute 
phase of stroke is associated with injury. The injurious 
role of AMPK in the acute phase of IR was supported by 
our data showing severe injury in AICAR, an AMPK acti-
vator, treated animals and reduced injury than IR in com-
pound c, an AMPK inhibitor, treated animals (Figure 6). 
Significantly reduced infarct volume and decreased 
functional deficits in peroxynitrite scavenger FeTPPS-
treated animals provide further evidence that the del-
eterious effect of nNOS/AMPK activities was caused by 
peroxynitrite (Figure  6). Because peroxynitrite activates 
AMPK via its upstream kinase LKB1 [60] and LKB1 acti-
vation can thus be down regulated by GSNO through 
reducing the levels of peroxynitrite in an nNOS inhibi-
tion-dependent pathway, GSNO shows potential to down 
regulate the nNOS/peroxynitrite/AMPK vicious cycle as 
depicted in Figure 7.
Conclusions
In the present study, we have shown that the nNOS/per-
oxynitrite/AMPK vicious cycle is an attractive therapeu-
tic target for stroke therapy. The study provides evidence 
that GSNO-mediated mechanisms of phosphorylation 
and dephosphorylation of nNOS and AMPK, in inhib-
iting aberrant nNOS and thus reducing peroxynitrite, 
protected against neuronal loss and aided in functional 
recovery following IR (Figure 7). GSNO is a natural mol-
ecule in the human brain and body, and its exogenous 
administration has not shown any evident toxicity or side 
effects in animals and humans [61, 62]. Therefore, GSNO 
seems to be an ideal interventional drug to provide neu-
roprotection and stimulate functional recovery in stroke.
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